Epristeride slow release preparation

Abstract

The present invention provides a kind of slow released epristeride preparation as 5alpha-reductase inhibiter for treating benign hyperplasia of prostate. The slow released epristeride preparation consists of epristeride 10-30 wt%, slow releasing supplementary material 30-60 wt%, and other supplementary material for the rest. The slow releasing supplementary material is hydropropyl methyl cellulose, ethyl cellulose, polyacrylate resin and / or polyhydroxy ethylene. The other supplementary material includes pore creating agent, filler, adhesive, lubricant, wetting agent, solvent and / or filming agent. The slow released epristeride preparation can maintain the blood medicine level for 24 hr and high curative effect.

Description

Technical field:

[0001] The invention relates to a pharmaceutical composition, in particular to a pharmaceutical composition for treating benign prostatic hyperplasia. Background technique:

[0002] Epristide, chemical name 17β-(N-tert-butyl-amino-formyl)androsta-3,5-diene-3-carboxylic acid, is a selective and non-competitive Steroid II type 5α-reductase inhibitors reduce the content of dihydrotestosterone in the prostate by inhibiting the conversion of testosterone into dihydrotestosterone, leading to atrophy of the prostatic body, and treating benign prostatic hyperplasia.

[0003] Aipriide tablets were developed and marketed by Jiangsu Lianhuan Pharmaceutical Co., Ltd. in 1999. They are ordinary tablets and are administered orally. Eprister elimination half-life (T 1 / 2 β) is 7.5 hours. Therefore, one tablet (5mg) is required for each Epride tablet, once in the morning and once a day, in order to maintain the effective blood concentration in the body and achieve the therapeutic...